1. Home
  2. XELB vs CVKD Comparison

XELB vs CVKD Comparison

Compare XELB & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

HOLD

Current Price

$1.42

Market Cap

10.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XELB
CVKD
Founded
2011
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medicinal Chemicals and Botanical Products
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
10.3M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
XELB
CVKD
Price
$1.42
$2.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$13.00
AVG Volume (30 Days)
75.6K
71.1K
Earning Date
04-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
48.37
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$2.29
52 Week High
$2.66
$14.64

Technical Indicators

Market Signals
Indicator
XELB
CVKD
Relative Strength Index (RSI) 33.58 29.23
Support Level $1.25 N/A
Resistance Level $1.62 $3.89
Average True Range (ATR) 0.15 0.40
MACD -0.03 -0.03
Stochastic Oscillator 2.30 4.79

Price Performance

Historical Comparison
XELB
CVKD

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: